[go: up one dir, main page]

EP3813880A4 - Antitumor immune checkpoint regulator antagonists - Google Patents

Antitumor immune checkpoint regulator antagonists Download PDF

Info

Publication number
EP3813880A4
EP3813880A4 EP19824955.9A EP19824955A EP3813880A4 EP 3813880 A4 EP3813880 A4 EP 3813880A4 EP 19824955 A EP19824955 A EP 19824955A EP 3813880 A4 EP3813880 A4 EP 3813880A4
Authority
EP
European Patent Office
Prior art keywords
immune checkpoint
antitumor immune
checkpoint regulator
regulator antagonists
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19824955.9A
Other languages
German (de)
French (fr)
Other versions
EP3813880A1 (en
Inventor
Jackie Z. SHENG
Bo Liu
Margaret Karow
Wei Zhang
Khue TRUONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gensun Biopharma Inc
Original Assignee
Gensun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensun Biopharma Inc filed Critical Gensun Biopharma Inc
Publication of EP3813880A1 publication Critical patent/EP3813880A1/en
Publication of EP3813880A4 publication Critical patent/EP3813880A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP19824955.9A 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists Pending EP3813880A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691658P 2018-06-29 2018-06-29
US201962823989P 2019-03-26 2019-03-26
PCT/US2019/039994 WO2020006516A1 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists

Publications (2)

Publication Number Publication Date
EP3813880A1 EP3813880A1 (en) 2021-05-05
EP3813880A4 true EP3813880A4 (en) 2022-07-13

Family

ID=68985227

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19826335.2A Pending EP3814381A4 (en) 2018-06-29 2019-06-28 TRISPECIFIC ANTAGONISTS
EP19824955.9A Pending EP3813880A4 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists
EP19826236.2A Withdrawn EP3813864A4 (en) 2018-06-29 2019-06-28 ANTITUMOR ANTAGONISTS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19826335.2A Pending EP3814381A4 (en) 2018-06-29 2019-06-28 TRISPECIFIC ANTAGONISTS

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19826236.2A Withdrawn EP3813864A4 (en) 2018-06-29 2019-06-28 ANTITUMOR ANTAGONISTS

Country Status (9)

Country Link
US (9) US11001635B2 (en)
EP (3) EP3814381A4 (en)
JP (3) JP2021532170A (en)
KR (1) KR20210028222A (en)
CN (3) CN113056285B (en)
AU (1) AU2019293047A1 (en)
BR (1) BR112020026862A2 (en)
CA (1) CA3105101A1 (en)
WO (3) WO2020006516A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN109071656B (en) * 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
BR112020017872A2 (en) 2018-03-02 2020-12-22 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES OF THE SAME
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
TWI760751B (en) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit and pd-1/tigit-binding molecules
WO2020263312A1 (en) * 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7495489B2 (en) * 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー，リミティド Recombinant proteins targeting PD-1 and TGFβ
IL292613A (en) 2019-11-01 2022-07-01 Ares Trading Sa Combined inhibition of pd-1, tgf-beta and atm along with radiotherapy for cancer treatment
BR112022008295A2 (en) 2019-11-05 2022-07-26 Merck Patent Gmbh COMBINED INHIBITION OF PD-1, TGFBETA AND TIGIT FOR THE TREATMENT OF CANCER
KR20220131261A (en) * 2020-01-10 2022-09-27 상하이 헨리우스 바이오테크, 인크. Anti-TIGIT antibody, multispecific antibody comprising same, and method of using same
KR20220107257A (en) * 2020-03-20 2022-08-02 레메젠 코, 리미티드 Bispecific fusion proteins and their applications
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
JP7711095B2 (en) * 2020-04-29 2025-07-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Bifunctional protein for PD-1 and TGF-β
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
WO2022059800A1 (en) * 2020-09-15 2022-03-24 Santen Pharmaceutical Co., Ltd. Bispecific binding molecules against vegf and ang2
WO2022090529A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
CA3196557A1 (en) 2020-11-02 2022-05-05 Ada SALA-HOJMAN Combination treatment of cancer
CN114539415B (en) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 anti-PD-L1/VEGF/TGF-beta multi-specific antibody and application thereof
WO2022132932A1 (en) * 2020-12-15 2022-06-23 The Trustees Of Columbia University In The City Of New York Method of enhancing immune response and cancer immunotherapy by targeting the cd58:cd2 axis
WO2022174451A1 (en) * 2021-02-22 2022-08-25 浙江道尔生物科技有限公司 Multi-domain fusion protein having anti-cancer activity
CN112940134B (en) * 2021-05-11 2021-09-03 正大天晴药业集团南京顺欣制药有限公司 Bifunctional proteins against PD-1 and TGF-beta
WO2022256820A1 (en) * 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
AU2022288037A1 (en) * 2021-06-09 2023-12-14 Shanghai Epimab Biotherapeutics Co., Ltd. Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
US20240352084A1 (en) 2021-07-22 2024-10-24 University Of Dundee Therapeutic muteins
US20240376207A1 (en) * 2021-09-15 2024-11-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
CN113773401B (en) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof
JP2024539164A (en) * 2021-10-21 2024-10-28 杭州阿諾生物医薬科技有限公司 A type of fusion polypeptide and its use
EP4455164A1 (en) * 2021-12-24 2024-10-30 Bio-Thera Solutions, Ltd. ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
JP2025503704A (en) * 2022-01-13 2025-02-04 インゲニア・セラピューティクス・インコーポレイテッド Fusion proteins binding VEGF and TIE2 and uses thereof
CN116496407B (en) * 2022-01-25 2025-08-15 上海菩莳医药科技有限公司 Double-function fusion protein and preparation method and application thereof
CN119110809A (en) 2022-02-23 2024-12-10 Xencor股份有限公司 Anti-CD28 x Anti-PSMA Antibodies
CN116836281A (en) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7H3 antibody and bifunctional antibody comprising same
KR20250048552A (en) * 2022-07-20 2025-04-09 밍훼이 파마슈티컬 (항저우) 리미티드 Multispecific antibodies and uses thereof
WO2024041477A1 (en) * 2022-08-22 2024-02-29 浙江道尔生物科技有限公司 Use of multi-domain fusion protein
WO2024218509A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
WO2025067442A1 (en) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Anti-fgfr2 antibody and multispecific binding molecule comprising same
WO2025076440A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. TGFβRII EXTRACELLULAR REGION VARIANTS AND USES THEREOF
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073282A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016191643A2 (en) * 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018128939A1 (en) * 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030025A (en) 1962-04-17 Thermostatic gas valve
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7067637B1 (en) 1992-02-12 2006-06-27 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Antibody or antibody fragments specific for a protein of the TGF-β family
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
EP1053330B1 (en) 1998-02-04 2005-05-04 Thromb-X N.V. Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU6085700A (en) 1999-07-12 2001-01-30 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
JP2001206899A (en) 1999-11-18 2001-07-31 Japan Tobacco Inc HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF
US6528959B2 (en) 2000-07-19 2003-03-04 Honda Giken Kogyo Kabushiki Kaisha Driving force control system for front-and-rear wheel drive vehicles
WO2002028408A2 (en) 2000-10-02 2002-04-11 Arizeke Pharmaceuticals, Inc. Compositions and methods for the transport of biologically active agents across cellular barriers
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6874679B2 (en) 2001-10-12 2005-04-05 Innovative Packaging Designs, L.P. Container having sliding corner support
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
CA2384922C (en) 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
US7025982B2 (en) 2002-09-19 2006-04-11 Medtronic, Inc. Medical assembly suitable for long-term implantation and method for fabricating the same
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7182135B2 (en) 2003-11-14 2007-02-27 Halliburton Energy Services, Inc. Plug systems and methods for using plugs in subterranean formations
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JP2008505928A (en) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド Therapeutic peptide
BRPI0517837A (en) 2004-11-12 2008-10-21 Xencor Inc fc variants with altered link to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA015584B1 (en) 2005-03-23 2011-10-31 Генмаб А/С ANTIBODY TO CD38 PERSON AND ITS APPLICATION
ES2657443T3 (en) 2005-03-25 2018-03-05 Gitr, Inc. Anti-GITR antibodies and uses thereof
ES2361269T3 (en) 2005-04-22 2011-06-15 Eli Lilly And Company SPECIFIC ANTIBODIES OF TGF BETA 1.
WO2006117910A1 (en) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Monoclonal antibody against platelet membrane glycoprotein vi
ITBS20050066A1 (en) 2005-06-01 2006-12-02 Sys Tec S R L METHOD AND MACHINE TO ALIGN FLEXOGRAPHIC PRINTING SHEETS ON PRINTING CYLINDERS
US8475798B2 (en) 2005-06-16 2013-07-02 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2007076391A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
WO2010030002A1 (en) 2008-09-12 2010-03-18 国立大学法人三重大学 Cell capable of expressing exogenous gitr ligand
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
GB0919074D0 (en) 2009-10-30 2009-12-16 Cambridge Reactor Design Ltd Crystallisation process and apparatus
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
IL300733B1 (en) * 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012299195B9 (en) 2011-08-19 2018-05-10 Regeneron Pharmaceuticals, Inc Anti-Tie2 antibodies uses thereof
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US8581886B2 (en) 2011-10-28 2013-11-12 Atmel Corporation Tuning algorithm for noise reduction in an active stylus
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
CA2865464C (en) 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Ang2-binding molecules
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
CN120365432A (en) 2012-11-21 2025-07-25 武汉友芝友生物制药股份有限公司 Bispecific Antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP3010525A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
DK3021869T3 (en) * 2013-07-16 2020-09-21 Hoffmann La Roche Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
SG11201606577YA (en) 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
KR102050082B1 (en) 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 Anti-tigit antibodies
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
CN107431522B (en) 2015-04-10 2021-03-16 Lg 电子株式会社 Method and device for reporting channel state information in a wireless communication system
CN111234027A (en) * 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
TWI773646B (en) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
CN105111314B (en) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 Novel fusion protein, pharmaceutical composition, preparation method and application thereof
EP3344660B1 (en) * 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
RU2744959C2 (en) 2016-03-23 2021-03-17 Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд New anti-pd-l1 antibodies
US10894823B2 (en) * 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
BR112018076260A2 (en) * 2016-06-20 2019-03-26 Kymab Limited antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
WO2020263312A1 (en) * 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN116390940A (en) * 2020-09-23 2023-07-04 海正生物制药有限公司 TGFBR2-ECD mutant and its fusion protein and application
WO2022256820A1 (en) * 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073282A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016191643A2 (en) * 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017218707A2 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018128939A1 (en) * 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists

Also Published As

Publication number Publication date
CN113056285A (en) 2021-06-29
US20200277388A1 (en) 2020-09-03
CN112739717A (en) 2021-04-30
CA3105101A1 (en) 2020-01-02
CN112739717B (en) 2025-02-11
US12404336B2 (en) 2025-09-02
US11518813B2 (en) 2022-12-06
CN112638401B (en) 2024-11-19
JP2021532170A (en) 2021-11-25
EP3814381A4 (en) 2022-08-10
US20210009696A1 (en) 2021-01-14
US20210246214A1 (en) 2021-08-12
US10647773B2 (en) 2020-05-12
KR20210028222A (en) 2021-03-11
EP3814381A1 (en) 2021-05-05
US20200002439A1 (en) 2020-01-02
US20200002417A1 (en) 2020-01-02
US20230331857A1 (en) 2023-10-19
CN113056285B (en) 2025-02-07
JP2021529556A (en) 2021-11-04
WO2020006509A1 (en) 2020-01-02
US20250361306A1 (en) 2025-11-27
AU2019293047A1 (en) 2021-01-28
WO2020006516A1 (en) 2020-01-02
BR112020026862A2 (en) 2021-04-20
EP3813880A1 (en) 2021-05-05
EP3813864A4 (en) 2022-07-20
US11001635B2 (en) 2021-05-11
US11667716B2 (en) 2023-06-06
EP3813864A1 (en) 2021-05-05
US20200181272A1 (en) 2020-06-11
US20200002426A1 (en) 2020-01-02
US11851493B2 (en) 2023-12-26
WO2020006511A1 (en) 2020-01-02
JP2021529557A (en) 2021-11-04
US10597453B2 (en) 2020-03-24
CN112638401A (en) 2021-04-09
US11945873B2 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
EP3813880A4 (en) Antitumor immune checkpoint regulator antagonists
PL3744756T3 (en) Acetoxy systems
EP3313892A4 (en) Immune checkpoint chimeric antigen receptors therapy
GB201909484D0 (en) Aircraft
CA187855S (en) Aircraft
GB201909480D0 (en) Aircraft
GB2580026B (en) Aircraft seat
GB201909478D0 (en) Aircraft
GB201909483D0 (en) Aircraft
IL273775B (en) Seismic yielding connection
EP3854683A4 (en) Aircraft
GB2589739B (en) Aircraft detection
EP3548405A4 (en) Composite belt profile
EP3892330A4 (en) Cxcr3 ligand
GB201909481D0 (en) Aircraft
GB201816660D0 (en) Aircraft assembly
EP3593385A4 (en) Integrated rectifier
GB2579885B (en) Aircraft
EP3914513C0 (en) Aircraft
GB2575072B (en) Demand regulator
SG11202011836YA (en) Meeting survey system
HK40115209A (en) Antagonists
HK40112153A (en) Synthetic controls for immunohistochemistry
HK40055560A (en) Antagonists
HK40056294A (en) Antagonists

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20220216BHEP

Ipc: C07K 16/28 20060101ALI20220216BHEP

Ipc: A61K 45/06 20060101ALI20220216BHEP

Ipc: A61K 39/395 20060101AFI20220216BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220613

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20220608BHEP

Ipc: C07K 16/28 20060101ALI20220608BHEP

Ipc: A61K 45/06 20060101ALI20220608BHEP

Ipc: A61K 39/395 20060101AFI20220608BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230705